Phylodynamics of HIV-1 from a Phase III AIDS Vaccine Trial in Bangkok, Thailand

被引:25
|
作者
Perez-Losada, Marcos [1 ]
Jobes, David V. [2 ]
Sinangil, Faruk [3 ]
Crandall, Keith A. [4 ]
Arenas, Miguel [5 ]
Posada, David [5 ]
Berman, Phillip W. [6 ]
机构
[1] Univ Porto, CIBIO, Ctr Invest Biodiversidade & Recursos Genet, Vairao, Portugal
[2] Jobes Consulting Serv, Rockville, MD USA
[3] Global Solut Infect Dis, San Francisco, CA USA
[4] Brigham Young Univ, Dept Biol, Provo, UT 84602 USA
[5] Univ Vigo, Dept Bioquim Genet & Inmunol, Vigo 36310, Spain
[6] Univ Calif Santa Cruz, Dept Biomol Engn, Santa Cruz, CA 95064 USA
来源
PLOS ONE | 2011年 / 6卷 / 03期
关键词
INJECTING DRUG-USERS; ESTIMATING EVOLUTIONARY RATES; MOLECULAR EPIDEMIOLOGY; SUBTYPE-B; TRANSMISSION CLUSTERS; GENOTYPIC CHARACTERIZATION; CIRCULATING RECOMBINANT; CRF01-AE/B RECOMBINANT; TYPE-1; INFECTION;
D O I
10.1371/journal.pone.0016902
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: In 2003, a phase III placebo-controlled trial (VAX003) was completed in Bangkok, Thailand. Of the 2,546 individuals enrolled in the trial based on high risk for infection through injection drug use (IDU), we obtained clinical samples and HIV-1 sequence data (envelope glycoprotein gene gp120) from 215 individuals who became infected during the trial. Here, we used these data in combination with other publicly available gp120 sequences to perform a molecular surveillance and phylodynamic analysis of HIV-1 in Thailand. Methodology and Findings: Phylogenetic and population genetic estimators were used to assess HIV-1 gp120 diversity as a function of vaccination treatment, viral load (VL) and CD4(+) counts, to indentify transmission clusters and to investigate the timescale and demographics of HIV-1 in Thailand. Three HIV-1 subtypes were identified: CRF01_AE (85% of the infections), subtype B (13%) and CRF15_AE (2%). The Bangkok IDU cohort showed more gp120 diversity than other Asian IDU cohorts and similar diversity to that observed in sexually infected individuals. Moreover, significant differences (P < 0.02) in genetic diversity were observed in CRF01_AE IDU with different VL and CD4(+) counts. No phylogenetic structure was detected regarding any of the epidemiological and clinical factors tested, although high proportions (35% to 50%) of early infections fell into clusters, which suggests that transmission chains associated with acute infection play a key role on HIV-1 spread among IDU. CRF01_AE was estimated to have emerged in Thailand in 1984.5 (1983-1986), 3-6 years before the first recognition of symptomatic patients (1989). The relative genetic diversity of the HIV-1 population has remained high despite decreasing prevalence rates since the mid 1990s. Conclusions: Our study and recent epidemiological reports indicate that HIV-1 is still a major threat in Thailand and suggest that HIV awareness and prevention needs to be strengthened to avoid AIDS resurgence.
引用
收藏
页数:10
相关论文
共 50 条
  • [11] Lessons from the RV144 Thai Phase III HIV-1 Vaccine Trial and the Search for Correlates of Protection
    Kim, Jerome H.
    Excler, Jean-Louis
    Michael, Nelson L.
    ANNUAL REVIEW OF MEDICINE, VOL 66, 2015, 66 : 423 - 437
  • [12] Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial
    Shaffer, N
    Chuachoowong, R
    Mock, PA
    Bhadrakom, C
    Siriwasin, W
    Young, NL
    Chotpitayasunondh, T
    Chearskul, S
    Roongpisuthipong, A
    Chinayon, P
    Karon, J
    Mastro, TD
    Simonds, RJ
    LANCET, 1999, 353 (9155): : 773 - 780
  • [13] Early markers of HIV-1 disease progression in a prospective cohort of seroconverters in Bangkok, Thailand - Implications for vaccine trials
    Buchacz, K
    Hu, DJ
    Vanichseni, S
    Mock, PA
    Chaowanachan, T
    Srisuwanvilai, LO
    Gvetadze, R
    van Griensven, F
    Tappero, JW
    Kitayaporn, D
    Kaewkungwal, J
    Choopanya, K
    Mastro, TD
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2004, 36 (03) : 853 - 860
  • [14] Phase III Trial of HIV Prime-Boost Vaccine Combination in Thailand: Follow Up Phase
    Rerks-Ngarm, S.
    Pitisuttithum, P.
    Nitayaphan, S.
    Kim, J.
    Kaewkungwal, J.
    Gurunathan, S.
    Gurwith, M.
    Michael, N.
    Khamboonruang, C.
    Thongcharoen, P.
    Kunasol, P.
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2008, 24 : 101 - 101
  • [15] Willingness of injection drug users to participate in an HIV vaccine efficacy trial in Bangkok, Thailand
    MacQueen, KM
    Vanichseni, S
    Kitayaporn, D
    Lin, LS
    Buavirat, A
    Naiwatanakul, T
    Raktham, S
    Mock, P
    Heyward, WL
    Des Jarlais, DC
    Choopanya, K
    Mastro, TD
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 1999, 21 (03): : 243 - 251
  • [16] AIDS - Preventing AIDS but not HIV-1 infection with a DNA vaccine
    Shen, XF
    Siliciano, RF
    SCIENCE, 2000, 290 (5491) : 463 - +
  • [18] The histopathology of HIV-1, subtype E, infected lymphoid tissue from Bangkok, Thailand.
    Frankel, S
    Klassen, M
    Markowitz, L
    Kiat, K
    Phaibul, P
    Tara, P
    Brown, A
    Nanta, R
    Sorachai, N
    Nelson, A
    Robb, M
    Birx, D
    LABORATORY INVESTIGATION, 1997, 76 (01) : 810 - 810
  • [19] THE EVOLVING MOLECULAR EPIDEMIOLOGY OF HIV-1 ENVELOPE SUBTYPES IN INJECTING DRUG-USERS IN BANGKOK, THAILAND - IMPLICATIONS FOR HIV VACCINE TRIALS
    KALISH, ML
    BALDWIN, A
    RAKTHAM, S
    WASI, C
    LUO, CC
    SCHOCHETMAN, G
    MASTRO, TD
    YOUNG, N
    VANICHSENI, S
    RUBSAMENWAIGMANN, H
    VONBRIESEN, H
    MULLINS, JI
    DELWART, E
    HERRING, B
    ESPARZA, J
    HEYWARD, WL
    OSMANOV, S
    AIDS, 1995, 9 (08) : 851 - 857
  • [20] AIDS - Diversity considerations in HIV-1 vaccine selection
    Gaschen, B
    Taylor, J
    Yusim, K
    Foley, B
    Gao, F
    Lang, D
    Novitsky, V
    Haynes, B
    Hahn, BH
    Bhattacharya, T
    Korber, B
    SCIENCE, 2002, 296 (5577) : 2354 - 2360